Last updated: September 23, 2026
Unoprostone isopropyl, marketed in the United States as Rescula, is a discontinued glaucoma drug with no meaningful current U.S. commercial market. The product received FDA approval in 2000 as a twice-daily ophthalmic solution for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.[1] Its commercial position weakened as once-daily prostaglandin analogs, including latanoprost, travoprost, and bimatoprost, gained prescribing share.
Public filings do not disclose a reliable standalone revenue series for Rescula. The available evidence supports a decline from a niche branded ophthalmology product to a discontinued asset with limited residual commercial value. The principal barriers to revival are weak differentiation, entrenched generic competition, uncertain supply economics, and the absence of a current U.S. patent-based exclusivity position.
What is unoprostone isopropyl and how does Rescula work?
Unoprostone isopropyl is a topical ophthalmic drug used to reduce elevated intraocular pressure. Rescula ophthalmic solution contained unoprostone isopropyl at a concentration of 0.15%, with recommended administration twice daily.[1]
Unoprostone is pharmacologically distinct from conventional prostaglandin F2α analogs. It is commonly described as a docosanoid derivative and potassium-channel modulator. The drug increases aqueous humor outflow through effects on the trabecular meshwork and uveoscleral pathways, reducing intraocular pressure without requiring systemic administration.[1]
| Attribute |
Unoprostone isopropyl |
| Brand |
Rescula |
| Dosage form |
Ophthalmic solution |
| Strength |
0.15% |
| FDA indication |
Open-angle glaucoma and ocular hypertension |
| Dosing |
Twice daily |
| U.S. approval |
2000 |
| Therapeutic class |
Intraocular-pressure-lowering ophthalmic |
| Current U.S. status |
Discontinued product |
| Biosimilar exposure |
None |
| Primary competitive alternatives |
Latanoprost, travoprost, bimatoprost, brimonidine, timolol, dorzolamide and fixed combinations |
When did unoprostone isopropyl lose exclusivity?
Unoprostone isopropyl no longer has meaningful U.S. regulatory exclusivity. The product was approved in 2000, and its commercial protection would have depended on patent term, regulatory exclusivity, and market-based differentiation rather than a current period of FDA exclusivity.
The FDA-approved product was a conventional small-molecule ophthalmic solution. It was not eligible for biologic exclusivity, and it did not receive the 12-year reference-product exclusivity applicable to biologics. Any Hatch-Waxman exclusivity period associated with the original NDA has long expired.[1][2]
U.S. exclusivity timeline
| Event |
Approximate timing |
Commercial significance |
| Original U.S. approval |
2000 |
Rescula entered the U.S. glaucoma market |
| Initial branded market period |
Early 2000s |
Competes with established topical glaucoma agents |
| Patent and regulatory exclusivity erosion |
2010s |
Limits ability to sustain premium pricing |
| U.S. product discontinuation |
Late 2010s or early 2020s |
Removes the active branded commercial platform |
| Current position |
2026 |
No active U.S. branded franchise of material scale |
The FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, lists discontinued products separately from currently marketed products. The listing of Rescula as discontinued does not itself determine whether all patents have expired, but it confirms that the product is not an active marketed reference product in the ordinary U.S. commercial channel.[2]
What patents protect unoprostone isopropyl?
The original intellectual-property position for unoprostone isopropyl was built around the active compound, prostaglandin-related chemistry, ophthalmic formulations, and methods of lowering intraocular pressure. The commercially relevant U.S. patent position has expired or no longer provides a practical barrier to entry.
Public patent databases contain multiple patents and patent families relating to unoprostone compounds and ophthalmic use. Patent scope varies by jurisdiction and claim type. Relevant categories include:
- Unoprostone isopropyl compounds and related derivatives.
- Ophthalmic compositions containing the active ingredient.
- Methods for treating glaucoma and ocular hypertension.
- Manufacturing processes for the active pharmaceutical ingredient.
- Stabilized or preserved ophthalmic formulations.
No current U.S. patent estate appears to provide a durable commercial moat around Rescula as a marketed product. Patent protection for a discontinued product also has limited economic value unless a sponsor can establish a commercially attractive formulation, delivery system, or new therapeutic indication.
Are there formulation patents for Rescula?
Formulation protection was potentially more important than compound protection because ophthalmic solutions require control of pH, tonicity, solubility, preservation, container compatibility, and chemical stability. A formulation patent could delay direct substitution if it covered a commercially necessary composition.
That protection is no longer sufficient to support a U.S. franchise. A generic sponsor may pursue a formulation that is pharmaceutically equivalent without duplicating every historical formulation claim. The FDA’s ophthalmic approval pathway permits competition based on pharmaceutical equivalence, bioequivalence where applicable, and clinical or analytical evidence appropriate to the product.[3]
What is the Orange Book status of Rescula?
Rescula is a discontinued FDA-approved ophthalmic product. The relevant reference product is unoprostone isopropyl ophthalmic solution, 0.15%, under NDA 20-519, historically associated with Novartis.[2]
The Orange Book implications are:
- The product is not a current growth asset in the U.S.
- There is no active period of brand exclusivity supporting premium pricing.
- Any historical listed patents should be reviewed against expiration, terminal disclaimers, and current listing status.
- A generic applicant’s filing strategy would depend on whether the reference product remains commercially available and whether FDA accepts it as the basis for an ANDA.
- Product discontinuation can complicate commercial launch even when technical approval is possible.
The distinction between FDA approval and active commercial availability matters. A discontinued NDA can remain part of the regulatory record, but the absence of a marketed product reduces the incentive for generic development and may require a sponsor to evaluate whether an alternative regulatory pathway is more efficient.
Which companies developed and marketed unoprostone isopropyl?
Unoprostone isopropyl was associated with Japanese ophthalmology research and was commercialized internationally through major pharmaceutical partners. Novartis marketed Rescula in the United States after FDA approval. Sucampo Pharmaceuticals later held U.S. commercial rights or commercial responsibility for the product as part of its ophthalmology portfolio.[4]
The ownership history reduced strategic value as the product matured. Large pharmaceutical companies typically prioritize ophthalmic assets with stronger growth, once-daily dosing, combination-product potential, or durable intellectual property. A niche twice-daily product with declining differentiation is vulnerable to divestment or discontinuation.
| Commercial factor |
Effect on unoprostone isopropyl |
| Twice-daily dosing |
Less convenient than once-daily prostaglandin analogs |
| Older mechanism |
Limited differentiation in a crowded class |
| Generic alternatives |
Strong price pressure across glaucoma therapy |
| Product concentration |
No broad platform or follow-on franchise |
| Manufacturing |
Sterile ophthalmic production raises fixed costs |
| Patent position |
No current high-value U.S. exclusivity barrier |
| Reimbursement |
Limited ability to sustain premium pricing |
| Market access |
Weak after U.S. discontinuation |
How did the competitive landscape affect Rescula sales?
The glaucoma market shifted toward prostaglandin analogs with once-daily dosing and strong intraocular-pressure reduction. Latanoprost became the principal reference product in the class, followed by travoprost and bimatoprost. Generic versions of these drugs substantially reduced treatment costs and expanded formulary access.
Rescula faced several disadvantages:
- Twice-daily administration compared with once-daily alternatives.
- Lower prescriber familiarity and weaker brand momentum.
- Limited evidence of superior efficacy or tolerability against leading competitors.
- Competition from beta blockers, alpha agonists, carbonic anhydrase inhibitors, and fixed-dose combinations.
- Broad generic availability in the glaucoma category.
- A treatment market increasingly managed through formulary substitution.
Unoprostone’s potential tolerability advantages did not create enough differentiation to offset these commercial disadvantages. Ophthalmologists could select from multiple generic products with established clinical use and lower acquisition costs.
What is the financial trajectory of unoprostone isopropyl?
The financial trajectory is best characterized as launch, niche commercialization, erosion, and discontinuation. Public company filings do not provide a consistent, audited, standalone revenue history for Rescula across its ownership changes. Reported product sales were generally aggregated within broader ophthalmology or pharmaceutical segments.
Financial trajectory
| Period |
Financial profile |
| 2000 to mid-2000s |
Branded launch into the U.S. glaucoma market |
| Mid-2000s to 2010s |
Niche revenue under pressure from established prostaglandin analogs |
| 2010s |
Reduced strategic importance as competition and generic substitution increased |
| Late 2010s onward |
Discontinuation and loss of recurring U.S. product revenue |
| Current period |
No material public U.S. revenue contribution |
The product’s economics were constrained by sterile manufacturing, limited volume, and the need to maintain regulatory compliance for an ophthalmic product with declining demand. Those costs are difficult to support when net pricing falls and prescribers have multiple substitutes.
What generic entry risks exist for unoprostone isopropyl?
A direct generic launch would face a mixed risk profile.
Regulatory risk
The reference product’s discontinued status may complicate the ANDA pathway. A generic sponsor would need to confirm that FDA considers the reference product suitable for an abbreviated application and that the product’s labeling, availability, and equivalence requirements can be satisfied.[3]
Commercial risk
The market opportunity is limited because Rescula no longer has a large active U.S. prescriber base. A generic product could face low demand even if approval were obtained.
Technical risk
Ophthalmic solutions require reproducible control of:
- Active-ingredient concentration.
- pH and osmolality.
- Sterility.
- Preservative performance.
- Container closure integrity.
- Impurity and degradation profiles.
These requirements can create manufacturing barriers, but they are not equivalent to durable patent protection.
Litigation risk
There is no current high-value patent litigation profile comparable to active blockbuster ophthalmic products. Historical Paragraph IV risk would have been concentrated around compound, formulation, and method-of-use patents. Given the age and discontinuation of the product, future litigation risk is low relative to the limited commercial opportunity.
Does unoprostone isopropyl have biosimilar risk?
No. Unoprostone isopropyl is a chemically synthesized small molecule, not a biologic. It is exposed to generic competition under the Hatch-Waxman framework rather than biosimilar competition under the Biologics Price Competition and Innovation Act.
The relevant competitive risks are ANDA approval, authorized generic substitution, therapeutic substitution, and competition from existing generic glaucoma medicines.
What licensing deals affected unoprostone isopropyl?
The product moved through commercial arrangements involving Novartis and Sucampo. Sucampo’s historical portfolio included Rescula alongside Amitiza and other specialty assets.[4] The commercial-rights transfers indicate that the asset was treated as a secondary product rather than a central growth platform.
No current licensing arrangement appears to support a significant U.S. commercial relaunch. The value of any future transaction would likely depend on non-U.S. rights, a reformulated product, a new delivery system, or a new indication rather than the legacy Rescula product alone.
What is the outlook for unoprostone isopropyl?
The U.S. outlook is weak. A relaunch would require a clear commercial rationale, such as:
- A meaningfully improved formulation.
- Once-daily or sustained-release delivery.
- A clinically differentiated tolerability profile.
- A new indication with limited competition.
- A low-cost manufacturing model.
- A regional market where the product remains approved and commercially recognized.
Without such differentiation, the product would compete against low-cost generics and established therapies. The legacy compound and historical ophthalmic patents do not create a strong current barrier to development.
Key Takeaways
- Unoprostone isopropyl was FDA-approved in 2000 as Rescula 0.15% ophthalmic solution.
- The product was dosed twice daily for open-angle glaucoma and ocular hypertension.
- Its market position weakened against once-daily prostaglandin analogs and generic glaucoma therapies.
- Rescula is discontinued in the U.S., with no material current U.S. revenue base.
- The product has no biosimilar exposure because it is a small molecule.
- Historical compound, formulation, and method-of-use patents no longer provide a meaningful U.S. commercial moat.
- Generic development is technically feasible but commercially unattractive without a differentiated formulation or delivery system.
- Public filings do not provide a reliable standalone revenue history for Rescula.
FAQs about unoprostone isopropyl
Is Rescula still available in the United States?
Rescula is listed as a discontinued FDA product and is not an active U.S. branded commercial product.[2]
Is unoprostone isopropyl the same as latanoprost?
No. Both reduce intraocular pressure, but they are different active ingredients with different pharmacologic profiles, dosing histories, and commercial positions.
Can a generic company still develop unoprostone isopropyl?
Potentially, but the commercial case is weak. The sponsor would need to address FDA pathway, sterile ophthalmic manufacturing, product availability, and limited market demand.
Does unoprostone isopropyl have active Orange Book patents?
No current high-value U.S. patent position appears to protect Rescula as a commercially active product. Historical listings must be checked against the current Orange Book and patent records.[2]
Why did unoprostone isopropyl lose market share?
The product was twice daily and lacked a decisive efficacy or convenience advantage over once-daily prostaglandin analogs and widely available generic glaucoma medicines.
References
-
U.S. Food and Drug Administration. (2009). Rescula (unoprostone isopropyl ophthalmic solution) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2023). ANDAs for certain highly purified synthetic peptides and ophthalmic drug products. FDA.
-
Sucampo Pharmaceuticals, Inc. (2014). Annual report on Form 10-K. U.S. Securities and Exchange Commission.
